An update of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (pts) with malignant pleural mesothelioma (MPM): A phase II clinical trial

被引：0

作者：

Janne, PA

Simon, GR

Langer, CJ

Taub, RN

Dowlati, A

Fidias, P

Bloss, LP

Ye, Z

Obasaju, C

Kindler, HL

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA

[3] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA

[4] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA

[5] Case Western Reserve Univ, Cleveland, OH 44106 USA

[6] Massachusetts Gen Hosp, Boston, MA 02114 USA

[7] Eli Lilly & Co, Indianapolis, IN 46285 USA

[8] Univ Chicago, Chicago, IL 60637 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：637S / 637S

页数：1

共 50 条

[1] An update of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (pts) with malignant pleural mesothelioma (MPM): A phase II clinical trial
Janne, P
Simon, G
Langer, C
Taub, R
Dowlati, A
Fidias, P
Bloss, L
Ye, Z
Obasaju, C
Kindler, H
LUNG CANCER, 2005, 49 : S282 - S282
[2] A phase 2 clinical trial of pemetrexed plus gemcitabine as front-line chemotherapy for patients with malignant pleural mesothelioma (MPM).
Janne, PA
Obasaju, C
Simon, G
Taub, R
Kelly, K
Fidias, P
Bloss, LP
Kindler, HL
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 629S - 629S
[3] A phase II study of pemetrexed and carboplatin as front-line chemotherapy in patients with malignant pleural mesothelioma (MPM)
Zucali, P. A.
Ceresoli, G. L.
Favaretto, A. G.
Cortinovis, D.
Grossi, F.
Marangolo, M.
Del Conte, G.
Ceribelli, A.
Bearz, A.
Parra, H. Soto
Santoro, A.
ANNALS OF ONCOLOGY, 2005, 16 : 28 - 28
[4] A phase II study of pemetrexed and carboplatin as front-line chemotherapy in patients with malignant pleural mesothelioma (MPM)
Parra, HS
Zucali, R
Favaretto, A
Grossi, F
Fusi, A
Marangolo, M
Del Conte, G
Ceribelli, A
Bearz, A
Ceresoli, G
LUNG CANCER, 2005, 49 : S229 - S229
[5] A phase 2 clinical trial of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with peritoneal mesothelioma (PM).
Simon, GR
Janne, PA
Langer, CJ
Verschraegen, CF
Dowlati, A
Gadgeel, SM
Kelly, K
Taylor, L
Obasaju, CK
Kindler, HL
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 679S - 679S
[6] A finalized phase II report of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with peritoneal mesothelioma (PM).
Simon, G. R.
Janne, P. A.
Langer, C.
Clarie, V.
Dowlati, A.
Gadgeel, S. M.
Kelly, K.
Ye, Z.
Obasaju, C. K.
Hood, K. E.
Kindler, H. L.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 91S - 91S
[7] Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma
Janne, Pasi A.
Simon, George R.
Langer, Corey J.
Taub, Robert N.
Dowlati, Afshin
Fidias, Panos
Monberg, Matthew
Obasaju, Coleman
Kindler, Hedy
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) : 1465 - 1471
[8] Pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (Pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC): A phase II clinical trial.
West, H
Belt, RJ
Wakelee, HA
Bloss, LP
Taylor, L
Monberg, MJ
Ye, Z
Obasaju, CK
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 649S - 649S
[9] A phase II study of pernetrexed and carboplatin as front-line chemotherapy in patients with malignant pleural mesothelimma (MPM).
Ceresoli, GL
Zucali, PA
Favaretto, A
Marangolo, M
Del Conte, G
Grossi, F
Ceribelli, A
Bidoli, P
Bearz, A
Santoro, A
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 663S - 663S
[10] Antimesothelin vaccine CRS-207 plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM).
Hassan, Raffit
Alley, Evan W.
Kindler, Hedy Lee
Antonia, Scott Joseph
Jahan, Thierry Marie
Jacobs-Small, Mona
Hull, Jennifer
McDougall, Katherine
Lemmens, Ed
Murphy, Aimee
Grous, John J.
Dubensky, Thomas
Brockstedt, Dirk G.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

← 1 2 3 4 5 →